抗粉样抗体是否会调节阿尔茨海默氏症患者的大脑功能?
Neuro-degenerative diseases
|December 13, 2025
概括
针对粉样质斑块的新型阿尔茨海默病治疗方法显示出适度的益处,但它们对大脑的影响尚不清楚. 功能性脑成像对于理解药物效应和指导未来阿尔茨海默氏症治疗至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 治疗方法,特别是针对粉样β (Aβ) 斑块的单克隆抗体,显示出适度的认知改善.
- 这些粉样清除疗法对整体大脑功能和大脑伪缩现象的确切影响仍然不太清楚.
研究的目的:
- 研究功能性大脑标记物的实用性,如FDG-PET,以阐明大脑伪缩的机制.
- 评估抗粉样蛋白疗法对神经活动和认知基质的影响.
- 倡导将多模式评估纳入AD临床试验.
主要方法:
- 对抗粉样蛋白抗体 (例如,莱卡内马布,多纳内马布,甘特内鲁马布) 的现有研究的审查.
- 功能性脑成像数据 (FDG-PET) 在粉样蛋白减少的背景下进行分析.
- 检查体积变化及其与粉样蛋白清除和神经退行相关的解释.
主要成果:
- 与抗Aβ抗体一起观察到的大脑伪缩,可能代表粉样蛋白清除的下游效应,而不是直接的神经退行.
- 像FDG-PET这样的功能标志物可以帮助区分伪缩与真正的神经退行,并评估药物对神经活动的影响.
- 在DIAN-TU-001试验中,Gantenerumab显示出显著的粉样蛋白减少,但没有检测到的代谢变化.
结论:
- 综合功能和结构性大脑标志物的多模式评估对于对阿尔茨海默氏症治疗疗效的全面评估至关重要.
- 未来针对阿尔茨海默病的疾病修饰试验应纳入功能和结构共同主终点.
- 这种方法将指导开发更有效的下一代AD治疗方法.
相关概念视频
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
512
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
512
03:03Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K